Published in Cancer Weekly, April 14th, 1997
The companies also announced that they have amended their agreement relating to Atragen. Preliminary safety data from an ongoing Phase II trial in APL indicate that Atragen was well tolerated, and reflected results obtained in the Phase I maximum tolerated dose trial. One hundred percent of first relapse patients (10 out of 10) have achieved a complete remission with Atragen monotherapy.
"At the end of 1997, we expect to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.